Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015, Article ID 436450, 12 pages
http://dx.doi.org/10.1155/2015/436450
Review Article

Therapeutic Potential of IL-17-Mediated Signaling Pathway in Autoimmune Liver Diseases

1Liver Unit and Center for Autoimmune Liver Diseases, Humanitas Clinical and Research Center, Via Manzoni 56, Rozzano, 20089 Milan, Italy
2State Key Laboratory for Oncogenes and Related Genes, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Division of Gastroenterology and Hepatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Cancer Institute, Shanghai Institute of Digestive Disease, 145 Middle Shandong Road, Shanghai 200001, China

Received 27 February 2015; Accepted 20 May 2015

Academic Editor: Jianfei Yang

Copyright © 2015 Haiyan Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. O. Chazouillères, D. Wendum, L. Serfaty, S. Montembault, O. Rosmorduc, and R. Poupon, “Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy,” Hepatology, vol. 28, no. 2, pp. 296–301, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. K. M. Boberg, R. W. Chapman, G. M. Hirschfield, A. W. Lohse, M. P. Manns, and E. Schrumpf, “Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue,” Journal of Hepatology, vol. 54, no. 2, pp. 374–385, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. J. S. Tzartos, M. A. Friese, M. J. Craner et al., “Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis,” The American Journal of Pathology, vol. 172, no. 1, pp. 146–155, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. M. A. Lowes, T. Kikuchi, J. Fuentes-Duculan et al., “Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells,” Journal of Investigative Dermatology, vol. 128, no. 5, pp. 1207–1211, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Azizi, F. Jadidi-Niaragh, and A. Mirshafiey, “Th17 Cells in Immunopathogenesis and treatment of rheumatoid arthritis,” International journal of rheumatic diseases, vol. 16, no. 3, pp. 243–253, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Rouvier, M.-F. Luciani, M.-G. Mattei, F. Denizot, and P. Golstein, “CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a Herpesvirus saimiri gene,” Journal of Immunology, vol. 150, no. 12, pp. 5445–5456, 1993. View at Google Scholar · View at Scopus
  7. T. Starnes, H. E. Broxmeyer, M. J. Robertson, and R. Hromas, “Cutting edge: IL-17D, a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis,” The Journal of Immunology, vol. 169, no. 2, pp. 642–646, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Lee, W.-H. Ho, M. Maruoka et al., “IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1,” The Journal of Biological Chemistry, vol. 276, no. 2, pp. 1660–1664, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. S. G. Hymowitz, E. H. Filvaroff, J. Yin et al., “IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding,” The EMBO Journal, vol. 20, no. 19, pp. 5332–5341, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Fossiez, O. Djossou, P. Chomarat et al., “T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines,” Journal of Experimental Medicine, vol. 183, no. 6, pp. 2593–2603, 1996. View at Publisher · View at Google Scholar · View at Scopus
  11. S. C. Liang, X.-Y. Tan, D. P. Luxenberg et al., “Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides,” The Journal of Experimental Medicine, vol. 203, no. 10, pp. 2271–2279, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. M. B. M. Teunissen, C. W. Koomen, R. de Waal Malefyt, E. A. Wierenga, and J. D. Bos, “Interleukin-17 and interferon-γ synergize in the enhancement of proinflammatory cytokine production by human keratinocytes,” Journal of Investigative Dermatology, vol. 111, no. 4, pp. 645–649, 1998. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Shen, Z. Hu, J. Goswami, and S. L. Gaffen, “Identification of common transcriptional regulatory elements in interleukin-17 target genes,” The Journal of Biological Chemistry, vol. 281, no. 34, pp. 24138–24148, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Dragon, M. S. Rahman, J. Yang, H. Unruh, A. J. Halayko, and A. S. Gounni, “IL-17 enhances IL-1β-mediated CXCL-8 release from human airway smooth muscle cells,” The American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 292, no. 4, pp. L1023–L1029, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. W. H. Faour, A. Mancini, Q. W. He, and J. A. Di Battista, “T-cell-derived interleukin-17 regulates the level and stability of cyclooxygenase-2 (COX-2) mRNA through restricted activation of the p38 mitogen-activated protein kinase cascade. Role of distal sequences in the 3′-untranslated region of COX-2 mRNA,” The Journal of Biological Chemistry, vol. 278, no. 29, pp. 26897–26907, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Laan, Z.-H. Cui, H. Hoshino et al., “Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways,” The Journal of Immunology, vol. 162, no. 4, pp. 2347–2352, 1999. View at Google Scholar · View at Scopus
  17. Y. Komiyama, S. Nakae, T. Matsuki et al., “IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis,” Journal of Immunology, vol. 177, no. 1, pp. 566–573, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. H. R. Conti, F. Shen, N. Nayyar et al., “Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis,” Journal of Experimental Medicine, vol. 206, no. 2, pp. 299–311, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Chen, W. Wang, H. Xie et al., “A pathogenic role of IL- 17 at the early stage of corneal allograft rejection,” Transplant Immunology, vol. 21, no. 3, pp. 155–161, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. W. J. Burlingham, R. B. Love, E. Jankowska-Gan et al., “IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants,” The Journal of Clinical Investigation, vol. 117, no. 11, pp. 3498–3506, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Martin-Orozco, P. Muranski, Y. Chung et al., “T helper 17 cells promote cytotoxic T cell activation in tumor immunity,” Immunity, vol. 31, no. 5, pp. 787–798, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Starnes, M. J. Robertson, G. Sledge et al., “Cutting edge: IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production,” Journal of Immunology, vol. 167, no. 8, pp. 4137–4140, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. S. H. Chang and C. Dong, “A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses,” Cell Research, vol. 17, no. 5, pp. 435–440, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Aggarwal, N. Ghilardi, M.-H. Xie, F. J. de Sauvage, and A. L. Gurney, “Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17,” Journal of Biological Chemistry, vol. 278, no. 3, pp. 1910–1914, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Hue, P. Ahern, S. Buonocore et al., “Interleukin-23 drives innate and T cell-mediated intestinal inflammation,” Journal of Experimental Medicine, vol. 203, no. 11, pp. 2473–2483, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. A. V. Rachitskaya, A. M. Hansen, R. Horai et al., “Cutting edge: NKT cells constitutively express IL-23 receptor and RORγt and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion,” Journal of Immunology, vol. 180, no. 8, pp. 5167–5171, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. H. H. Uhlig, B. S. McKenzie, S. Hue et al., “Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology,” Immunity, vol. 25, no. 2, pp. 309–318, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. D. J. Cua and C. M. Tato, “Innate IL-17-producing cells: the sentinels of the immune system,” Nature Reviews Immunology, vol. 10, no. 7, pp. 479–489, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. S. L. Gaffen, “Structure and signalling in the IL-17 receptor family,” Nature Reviews Immunology, vol. 9, no. 8, pp. 556–567, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Ishigame, S. Kakuta, T. Nagai et al., “Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses,” Immunity, vol. 30, no. 1, pp. 108–119, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Hizawa, M. Kawaguchi, S.-K. Huang, and M. Nishimura, “Role of interleukin-17F in chronic inflammatory and allergic lung disease,” Clinical and Experimental Allergy, vol. 36, no. 9, pp. 1109–1114, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. X. O. Yang, S. H. Chang, H. Park et al., “Regulation of inflammatory responses by IL-17F,” Journal of Experimental Medicine, vol. 205, no. 5, pp. 1063–1075, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. Y.-H. Wang, P. Angkasekwinai, N. Lu et al., “IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells,” The Journal of Experimental Medicine, vol. 204, no. 8, pp. 1837–1847, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Sharkhuu, K. I. Matthaei, E. Forbes et al., “Mechanism of interleukin-25 (IL-17E)-induced pulmonary inflammation and airways hyper-reactivity,” Clinical and Experimental Allergy, vol. 36, no. 12, pp. 1575–1583, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. J. L. Barlow and A. N. J. McKenzie, “IL-25: a key requirement for the regulation of type-2 immunity,” BioFactors, vol. 35, no. 2, pp. 178–182, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Li, J. Chen, A. Huang et al., “Cloning and characterization of IL-17B and IL-17C, two new members of the IL-17 cytokine family,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 2, pp. 773–778, 2000. View at Publisher · View at Google Scholar · View at Scopus
  37. L. van Maele, C. Carnoy, D. Cayet et al., “TLR5 signaling stimulates the innate production of IL-17 and IL-22 by CD3negCD127+ immune cells in spleen and mucosa,” Journal of Immunology, vol. 185, no. 2, pp. 1177–1185, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. D. B. Holland, R. A. Bojar, M. D. Farrar, and K. T. Holland, “Differential innate immune responses of a living skin equivalent model colonized by Staphylococcus epidermidis or Staphylococcus aureus,” FEMS Microbiology Letters, vol. 290, no. 2, pp. 149–155, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Yamaguchi, K. Fujio, H. Shoda et al., “IL-17B and IL-17C are associated with TNF-α production and contribute to the exacerbation of inflammatory arthritis,” The Journal of Immunology, vol. 179, no. 10, pp. 7128–7136, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. Z. Yao, W. C. Fanslow, M. F. Seldin et al., “Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor,” Immunity, vol. 3, no. 6, pp. 811–821, 1995. View at Publisher · View at Google Scholar · View at Scopus
  41. Z. Yao, M. K. Spriggs, J. M. J. Derry et al., “Molecular characterization of the human interleukin (IL)-17 receptor,” Cytokine, vol. 9, no. 11, pp. 794–800, 1997. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. Sonobe, H. Takeuchi, K. Kataoka et al., “Interleukin-25 expressed by brain capillary endothelial cells maintains blood-brain barrier function in a protein kinase Cε-dependent manner,” The Journal of Biological Chemistry, vol. 284, no. 46, pp. 31834–31842, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Lajoie-Kadoch, P. Joubert, S. Létuvé et al., “TNF-α and IFN-γ inversely modulate expression of the IL-17E receptor in airway smooth muscle cells,” The American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 290, no. 6, pp. L1238–L1246, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Terashima, H. Watarai, S. Inoue et al., “A novel subset of mouse NKT cells bearing the IL-17 receptor B responds to IL-25 and contributes to airway hyperreactivity,” Journal of Experimental Medicine, vol. 205, no. 12, pp. 2727–2733, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. E. A. Rickel, L. A. Siegel, P. Y. Bo-Rin et al., “Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities,” The Journal of Immunology, vol. 181, no. 6, pp. 4299–4310, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. R. E. Kuestner, D. W. Taft, A. Haran et al., “Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F,” The Journal of Immunology, vol. 179, no. 8, pp. 5462–5473, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. D. Ge and Z. You, “Expression of interleukin-17RC protein in normal human tissues,” International Archives of Medicine, vol. 1, no. 1, article 19, 2008. View at Publisher · View at Google Scholar
  48. Z. Rong, A. Wang, Z. Li et al., “IL-17RD (Sef or IL-17RLM) interacts with IL-17 receptor and mediates IL-17 signaling,” Cell Research, vol. 19, no. 2, pp. 208–215, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. T.-S. Li, X.-N. Li, Z.-J. Chang, X.-Y. Fu, and L. Liu, “Identification and functional characterization of a novel interleukin 17 receptor: a possible mitogenic activation through ras/mitogen-activated protein kinase signaling pathway,” Cellular Signalling, vol. 18, no. 8, pp. 1287–1298, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. T. A. Moseley, D. R. Haudenschild, L. Rose, and A. H. Reddi, “Interleukin-17 family and IL-17 receptors,” Cytokine and Growth Factor Reviews, vol. 14, no. 2, pp. 155–174, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Hot and P. Miossec, “Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes,” Annals of the Rheumatic Diseases, vol. 70, no. 5, pp. 727–732, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Zhu, W. Pan, P. Shi et al., “Modulation of experimental autoimmune encephalomyelitis through TRAF3-mediated suppression of interleukin 17 receptor signaling,” The Journal of Experimental Medicine, vol. 207, no. 12, pp. 2647–2662, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. L. Zhao, Y. Tang, Z. You et al., “Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression,” PLoS ONE, vol. 6, no. 4, Article ID e18909, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. H. Yu, J. Huang, Y. Liu et al., “IL-17 contributes to autoimmune hepatitis,” Journal of Huazhong University of Science and Technology [Medical Sciences], vol. 30, no. 4, pp. 443–446, 2010. View at Publisher · View at Google Scholar
  55. C. R. Grant, R. Liberal, B. S. Holder et al., “Dysfunctional CD39POS regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis,” Hepatology, vol. 59, no. 3, pp. 1007–1015, 2014. View at Publisher · View at Google Scholar · View at Scopus
  56. M. S. Longhi, R. Liberal, B. Holder et al., “Inhibition of interleukin-17 promotes differentiation of CD25- cells into stable T regulatory cells in patients with autoimmune hepatitis,” Gastroenterology, vol. 142, no. 7, pp. 1526.e6–1535.e6, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. M. P. Manns, A. J. Czaja, J. D. Gorham et al., “Diagnosis and management of autoimmune hepatitis,” Hepatology, vol. 51, no. 6, pp. 2193–2213, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. C. Qian, T. Jiang, W. Zhang et al., “Increased IL-23 and IL-17 expression by peripheral blood cells of patients with primary biliary cirrhosis,” Cytokine, vol. 64, no. 1, pp. 172–180, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. R. Y. Z. Lan, T. L. Salunga, K. Tsuneyama et al., “Hepatic IL-17 responses in human and murine primary biliary cirrhosis,” Journal of Autoimmunity, vol. 32, no. 1, pp. 43–51, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. K. Harada, S. Shimoda, Y. Sato, K. Isse, H. Ikeda, and Y. Nakanuma, “Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis,” Clinical and Experimental Immunology, vol. 157, no. 2, pp. 261–270, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. C.-Y. Yang, X. Ma, K. Tsuneyama et al., “IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy,” Hepatology, vol. 59, no. 5, pp. 1944–1953, 2014. View at Publisher · View at Google Scholar · View at Scopus
  62. K. Harada, S. Shimoda, H. Ikeda et al., “Significance of periductal Langerhans cells and biliary epithelial cell-derived macrophage inflammatory protein-3α in the pathogenesis of primary biliary cirrhosis,” Liver International, vol. 31, no. 2, pp. 245–253, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. W. Hsu, W. Zhang, K. Tsuneyama et al., “Differential mechanisms in the pathogenesis of autoimmune cholangitis versus inflammatory bowel disease in interleukin-2Rα-/- mice,” Hepatology, vol. 49, no. 1, pp. 133–140, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. K. Kawata, M. Tsuda, G.-X. Yang et al., “Identification of potential cytokine pathways for therapeutic intervention in murine primary biliary cirrhosis,” PLoS ONE, vol. 8, no. 9, Article ID e74225, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. C.-Y. Yang, P. S. C. Leung, G.-X. Yang et al., “Epitope-specific anti-nuclear antibodies are expressed in a mouse model of primary biliary cirrhosis and are cytokine-dependent,” Clinical and Experimental Immunology, vol. 168, no. 3, pp. 261–267, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. J. Katt, D. Schwinge, T. Schoknecht et al., “Increased T helper type 17 response to pathogen stimulation in patients with primary sclerosing cholangitis,” Hepatology, vol. 58, no. 3, pp. 1084–1093, 2013. View at Publisher · View at Google Scholar · View at Scopus
  67. H. Kulaksiz, G. Rudolph, P. Kloeters-Plachky, P. Sauer, H. Geiss, and A. Stiehl, “Biliary candida infections in primary sclerosing cholangitis,” Journal of Hepatology, vol. 45, no. 5, pp. 711–716, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. F. Meng, K. Wang, T. Aoyama et al., “Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice,” Gastroenterology, vol. 143, no. 3, pp. 765–776, 2012. View at Publisher · View at Google Scholar · View at Scopus
  69. M. Hara, H. Kono, S. Furuya, K. Hirayama, M. Tsuchiya, and H. Fujii, “Interleukin-17A plays a pivotal role in cholestatic liver fibrosis in mice,” Journal of Surgical Research, vol. 183, no. 2, pp. 574–582, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. Y. Zheng, D. M. Danilenko, P. Valdez et al., “Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis,” Nature, vol. 445, no. 7128, pp. 648–651, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. A. Ogawa, A. Andoh, Y. Araki, T. Bamba, and Y. Fujiyama, “Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice,” Clinical Immunology, vol. 110, no. 1, pp. 55–62, 2004. View at Publisher · View at Google Scholar · View at Scopus
  72. E. Lubberts, M. I. Koenders, B. Oppers-Walgreen et al., “Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion,” Arthritis and Rheumatism, vol. 50, no. 2, pp. 650–659, 2004. View at Publisher · View at Google Scholar · View at Scopus
  73. H.-C. Hsu, P. Yang, J. Wang et al., “Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice,” Nature Immunology, vol. 9, no. 2, pp. 166–175, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. M. S. Longhi, Y. Ma, G. Mieli-Vergani, and D. Vergani, “Aetiopathogenesis of autoimmune hepatitis,” Journal of Autoimmunity, vol. 34, no. 1, pp. 7–14, 2010. View at Publisher · View at Google Scholar · View at Scopus
  75. I. N. Crispe, “The liver as a lymphoid organ,” Annual Review of Immunology, vol. 27, pp. 147–163, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. M. S. Longhi, M. J. Hussain, R. R. Mitry et al., “Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis,” The Journal of Immunology, vol. 176, no. 7, pp. 4484–4491, 2006. View at Publisher · View at Google Scholar · View at Scopus
  77. S. Ferri, M. S. Longhi, C. de Molo et al., “A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis,” Hepatology, vol. 52, no. 3, pp. 999–1007, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. S. Sakaguchi, K. Fukuma, K. Kuribayashi, and T. Masuda, “Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease,” The Journal of Experimental Medicine, vol. 161, no. 1, pp. 72–87, 1985. View at Publisher · View at Google Scholar · View at Scopus
  79. J. M. Fletcher, R. Lonergan, L. Costelloe et al., “CD39+Foxp3+ regulatory T cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis,” Journal of Immunology, vol. 183, no. 11, pp. 7602–7610, 2009. View at Publisher · View at Google Scholar · View at Scopus
  80. M. S. Longhi, F. Meda, P. Wang et al., “Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis,” Hepatology, vol. 47, no. 2, pp. 581–591, 2008. View at Publisher · View at Google Scholar · View at Scopus
  81. P. Invernizzi, C. Selmi, and M. E. Gershwin, “Update on primary biliary cirrhosis,” Digestive and Liver Disease, vol. 42, no. 6, pp. 401–408, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. K. D. Lindor, M. E. Gershwin, R. Poupon, M. Kaplan, N. V. Bergasa, and E. J. Heathcote, “Primary biliary cirrhosis,” Hepatology, vol. 50, no. 1, pp. 291–308, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. G. Syal, M. Fausther, and J. A. Dranoff, “Advances in cholangiocyte immunobiology,” The American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 303, no. 10, pp. G1077–G1086, 2012. View at Publisher · View at Google Scholar · View at Scopus
  84. G. Ballardini, M. Fallani, F. B. Bianchi, and E. Pisi, “Antigen presenting cells in liver biopsies from patients with primary biliary cirrhosis,” Autoimmunity, vol. 3, no. 2, pp. 135–144, 1989. View at Publisher · View at Google Scholar · View at Scopus
  85. S. Oertelt, Z.-X. Lian, C.-M. Cheng et al., “Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-β receptor II dominant-negative mice,” The Journal of Immunology, vol. 177, no. 3, pp. 1655–1660, 2006. View at Publisher · View at Google Scholar · View at Scopus
  86. M. Nakamura, H. Kondo, T. Mori et al., “Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis,” Hepatology, vol. 45, no. 1, pp. 118–127, 2007. View at Publisher · View at Google Scholar · View at Scopus
  87. S. Itoh, T. Ichida, T. Yoshida et al., “Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis,” Journal of Gastroenterology and Hepatology, vol. 13, no. 3, pp. 257–265, 1998. View at Publisher · View at Google Scholar · View at Scopus
  88. Y.-M. Lee and M. M. Kaplan, “Primary sclerosing cholangitis,” The New England Journal of Medicine, vol. 332, no. 14, pp. 924–933, 1995. View at Publisher · View at Google Scholar · View at Scopus
  89. P. Angulo and K. D. Lindor, “Primary sclerosing cholangitis,” Hepatology, vol. 30, no. 1, pp. 325–332, 1999. View at Publisher · View at Google Scholar · View at Scopus
  90. J. E. Eaton, J. A. Talwalkar, K. N. Lazaridis, G. J. Gores, and K. D. Lindor, “Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management,” Gastroenterology, vol. 145, no. 3, pp. 521–536, 2013. View at Publisher · View at Google Scholar · View at Scopus
  91. G. M. Hirschfield, T. H. Karlsen, K. D. Lindor, and D. H. Adams, “Primary sclerosing cholangitis,” The Lancet, vol. 382, no. 9904, pp. 1587–1599, 2013. View at Publisher · View at Google Scholar · View at Scopus
  92. G. Rudolph, D. Gotthardt, P. Klöters-Plachky, H. Kulaksiz, D. Rost, and A. Stiehl, “Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis,” Journal of Hepatology, vol. 51, no. 1, pp. 149–155, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. P. Fickert, G. Zollner, A. Fuchsbichler et al., “Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles,” Gastroenterology, vol. 123, no. 4, pp. 1238–1251, 2002. View at Publisher · View at Google Scholar · View at Scopus
  94. M. J. Pollheimer, M. Trauner, and P. Fickert, “Will we ever model PSC?—‘it's hard to be a PSC model!’,” Clinics and Research in Hepatology and Gastroenterology, vol. 35, no. 12, pp. 792–804, 2011. View at Publisher · View at Google Scholar · View at Scopus
  95. A. Chiricozzi, E. Guttman-Yassky, M. Suárez-Farĩas et al., “Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis,” Journal of Investigative Dermatology, vol. 131, no. 3, pp. 677–687, 2011. View at Publisher · View at Google Scholar · View at Scopus
  96. S. Fujino, A. Andoh, S. Bamba et al., “Increased expression of interleukin 17 in inflammatory bowel disease,” Gut, vol. 52, no. 1, pp. 65–70, 2003. View at Publisher · View at Google Scholar · View at Scopus
  97. S. Kotake, N. Udagawa, N. Takahashi et al., “IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis,” The Journal of Clinical Investigation, vol. 103, no. 9, pp. 1345–1352, 1999. View at Publisher · View at Google Scholar · View at Scopus
  98. G. Dong, R. Ye, W. Shi et al., “IL-17 induces autoantibody overproduction and peripheral blood mononuclear cell overexpression of IL-6 in lupus nephritis patients,” Chinese Medical Journal, vol. 116, no. 4, pp. 543–548, 2003. View at Google Scholar · View at Scopus
  99. S. Zhu and Y. Qian, “IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential,” Clinical Science, vol. 122, no. 11, pp. 487–511, 2012. View at Publisher · View at Google Scholar · View at Scopus
  100. K. A. Papp, R. G. Langley, B. Sigurgeirsson et al., “Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study,” British Journal of Dermatology, vol. 168, no. 2, pp. 412–421, 2013. View at Publisher · View at Google Scholar · View at Scopus
  101. C. Leonardi, R. Matheson, C. Zachariae et al., “Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis,” The New England Journal of Medicine, vol. 366, no. 13, pp. 1190–1191, 2012. View at Publisher · View at Google Scholar · View at Scopus
  102. K. A. Papp, C. Leonardi, A. Menter et al., “Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis,” The New England Journal of Medicine, vol. 366, no. 13, pp. 1181–1189, 2012. View at Publisher · View at Google Scholar · View at Scopus
  103. M. T. Tse, “IL-17 antibodies gain momentum,” Nature Reviews Drug Discovery, vol. 12, no. 11, pp. 815–816, 2013. View at Publisher · View at Google Scholar · View at Scopus
  104. M. C. Genovese, P. Durez, H. B. Richards et al., “Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study,” Annals of the Rheumatic Diseases, vol. 72, no. 6, pp. 863–869, 2013. View at Publisher · View at Google Scholar · View at Scopus
  105. D. Baeten, X. Baraliakos, J. Braun et al., “Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial,” The Lancet, vol. 382, pp. 1705–1713, 2013. View at Publisher · View at Google Scholar
  106. A. D. Dick, I. Tugal-Tutkun, S. Foster et al., “Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials,” Ophthalmology, vol. 120, no. 4, pp. 777–787, 2013. View at Publisher · View at Google Scholar · View at Scopus
  107. M. C. Genovese, M. Greenwald, C. S. Cho et al., “A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors,” Arthritis & Rheumatism, vol. 66, no. 7, pp. 1693–1704, 2014. View at Publisher · View at Google Scholar
  108. W. Hueber, B. E. Sands, S. Lewitzky et al., “Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: Unexpected results of a randomised, double-blindplacebo-controlled trial,” Gut, vol. 61, no. 12, pp. 1693–1700, 2012. View at Publisher · View at Google Scholar · View at Scopus
  109. D. Toy, D. Kugler, M. Wolfson et al., “Cutting edge: interleukin 17 signals through a heteromeric receptor complex,” Journal of Immunology, vol. 177, no. 1, pp. 36–39, 2006. View at Publisher · View at Google Scholar · View at Scopus
  110. S. Zrioual, M.-L. Toh, A. Tournadre et al., “IL-17RA and IL-17RC receptors are essential for IL-17A-induced ELR+ CXC chemokine expression in synoviocytes and are overexpressed in rheumatoid blood,” Journal of Immunology, vol. 180, no. 1, pp. 655–663, 2008. View at Publisher · View at Google Scholar · View at Scopus
  111. R. Pappu, V. Ramirez-Carrozzi, N. Ota, W. Ouyang, and Y. Hu, “The IL-17 family cytokines in immunity and disease,” Journal of Clinical Immunology, vol. 30, no. 2, pp. 185–195, 2010. View at Publisher · View at Google Scholar · View at Scopus
  112. C. Ritchlin, P. Rahman, A. Kavanaugh et al., “Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled,” Annals of the Rheumatic Diseases, vol. 73, no. 6, pp. 990–999, 2014. View at Publisher · View at Google Scholar · View at Scopus
  113. W. J. Sandborn, C. Gasink, L.-L. Gao et al., “Ustekinumab induction and maintenance therapy in refractory Crohn's disease,” The New England Journal of Medicine, vol. 367, no. 16, pp. 1519–1528, 2012. View at Publisher · View at Google Scholar · View at Scopus
  114. C. E. M. Griffiths, B. E. Strober, P. van de Kerkhof et al., “Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis,” The New England Journal of Medicine, vol. 362, no. 2, pp. 118–128, 2010. View at Publisher · View at Google Scholar · View at Scopus
  115. K. A. Papp, C. E. M. Griffiths, K. Gordon et al., “Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up,” British Journal of Dermatology, vol. 168, no. 4, pp. 844–854, 2013. View at Publisher · View at Google Scholar · View at Scopus
  116. P. Miossec and J. K. Kolls, “Targeting IL-17 and TH17 cells in chronic inflammation,” Nature Reviews Drug Discovery, vol. 11, no. 10, pp. 763–776, 2012. View at Publisher · View at Google Scholar · View at Scopus
  117. A. Shetty, R. Hanson, P. Korsten et al., “Tocilizumab in the treatment of rheumatoid arthritis and beyond,” Drug Design, Development and Therapy, vol. 8, pp. 349–364, 2014. View at Publisher · View at Google Scholar · View at Scopus
  118. J. E. Frampton, “Tocilizumab: a review of its use in the treatment of juvenile idiopathic arthritis,” Pediatric Drugs, vol. 15, no. 6, pp. 515–531, 2013. View at Publisher · View at Google Scholar · View at Scopus
  119. M. Geyer and U. Müller-Ladner, “Actual status of antiinterleukin-1 therapies in rheumatic diseases,” Current Opinion in Rheumatology, vol. 22, no. 3, pp. 246–251, 2010. View at Publisher · View at Google Scholar · View at Scopus
  120. J. R. Huh, E. E. Englund, H. Wang et al., “Identification of potent and selective diphenylpropanamide RORγ inhibitors,” ACS Medicinal Chemistry Letters, vol. 4, no. 1, pp. 79–84, 2013. View at Publisher · View at Google Scholar · View at Scopus
  121. P. M. Khan, B. E.-D. M. El-Gendy, N. Kumar et al., “Small molecule amides as potent ROR-γ selective modulators,” Bioorganic and Medicinal Chemistry Letters, vol. 23, no. 2, pp. 532–536, 2013. View at Publisher · View at Google Scholar · View at Scopus
  122. S. C. P. Williams, “Flurry of deal-making surrounds new autoimmunity target,” Nature Medicine, vol. 19, no. 9, article 1078, 2013. View at Google Scholar · View at Scopus
  123. L. A. Solt, N. Kumar, P. Nuhant et al., “Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand,” Nature, vol. 472, no. 7344, pp. 491–494, 2011. View at Publisher · View at Google Scholar · View at Scopus
  124. P. Delerive, W. W. Chin, and C. S. Suen, “Identification of Reverbα as a novel RORα target gene,” Journal of Biological Chemistry, vol. 277, no. 38, pp. 35013–35018, 2002. View at Publisher · View at Google Scholar · View at Scopus
  125. J. Wang, L. Yin, and M. A. Lazar, “The orphan nuclear receptor Rev-erbα regulates circadian expression of plasminogen activator inhibitor type 1,” The Journal of Biological Chemistry, vol. 281, no. 45, pp. 33842–33848, 2006. View at Publisher · View at Google Scholar · View at Scopus
  126. T. Wada, S. K. Hong, M. Angers et al., “Identification of oxysterol 7α-hydroxylase (Cyp7b1) as a novel retinoid-related orphan receptor α (RORα) (NR1F1) target gene and a functional cross-talk between RORα and liver X receptor (NR1H3),” Molecular Pharmacology, vol. 73, no. 3, pp. 891–899, 2008. View at Publisher · View at Google Scholar · View at Scopus
  127. N. Kumar, B. Lyda, M. R. Chang et al., “Identification of SR2211: a potent synthetic RORγ-selective modulator,” ACS Chemical Biology, vol. 7, no. 4, pp. 672–677, 2012. View at Publisher · View at Google Scholar · View at Scopus
  128. E. ELinghaus, D. ELinghaus, P. E. Stuart et al., “Genome-wide asociation study identifies a psoriasis susceptibility locus at TRAF3IP2,” Nature Genetics, vol. 42, no. 11, pp. 991–995, 2010. View at Publisher · View at Google Scholar · View at Scopus
  129. U. Hüffmeier, S. Uebe, A. B. Ekici et al., “CoMon variants at TRAF3IP2 are aSociated with susceptibility to psoriatic arthritis and psoriasis,” Nature Genetics, vol. 42, no. 11, pp. 996–999, 2010. View at Publisher · View at Google Scholar · View at Scopus
  130. C. Liu, S. Swaidani, W. Qian et al., “A CC' loop decoy peptide blocks the interaction between Act1 and IL-17RA to attenuate IL-17- and IL-25-induced inflammation,” Science Signaling, vol. 4, no. 197, article ra72, 2011. View at Publisher · View at Google Scholar · View at Scopus
  131. F. Shen and S. L. Gaffen, “Structure-function relationships in the IL-17 receptor: implications for signal transduction and therapy,” Cytokine, vol. 41, no. 2, pp. 92–104, 2008. View at Publisher · View at Google Scholar · View at Scopus